Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Faber

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
CNS Drugs|October 17, 2025
The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI CohortPatrick Silva, Marina A Costa, Laetitia Gaspar, et al.
Neurobiology of Disease|February 29, 2024
Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph diseaseMafalda Raposo, Jeannette Hübener-Schmid, Rebecca Tagett, et al.
The Lancet Regional Health. Europe|January 5, 2026
Patient-reported, psychosocial and health economic outcomes in mild to moderate Friedreich's ataxia: baseline results of the PROFA studyMarcus Grobe-Einsler, Stéphanie Borel, Maresa Buchholz, et al.
Annals of Neurology|December 13, 2022
Clinically Meaningful Magnetic Resonance Endpoints Sensitive to Preataxic Spinocerebellar Ataxia Types 1 and 3Jayashree Chandrasekaran, Emilien Petit, Young Woo Park, et al.
Journal of Neurology|November 3, 2022
The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factorsHolger Hengel, Peter Martus, Jennifer Faber, et al.
Journal of Neurology|November 18, 2023
Correction to: The frequency of non‑motor symptoms in SCA3 and their association with disease severity and lifestyle factorsHolger Hengel, Peter Martus, Jennifer Faber, et al.
Neuropathology and Applied Neurobiology|February 17, 2023
A standardised protocol for blood and cerebrospinal fluid collection and processing for biomarker research in ataxiaMagda M Santana, Laetitia S Gaspar, Maria M Pinto, et al.
Ebiomedicine|November 28, 2025
Quantitative susceptibility mapping at 7T as a biomarker of post- and interictal extravascular iron in patients with focal epilepsyNina Rebecca Held, Tobias Bauer, Rüdiger Stirnberg, et al.
Journal of Neurology|April 17, 2025
Optimizing selectivity of the Cerebellar Cognitive Affective Syndrome Scale by use of correction formulas, and validation of its German versionAndreas Thieme, Kerstin Rubarth, Raquel van der Veen, et al.
Journal of Neurology|December 21, 2024
Subtypes of cognitive impairment in cerebellar disease identified by cross-diagnostic cluster-analysis: results from a German multicenter studyQi Liu, Kerstin Rubarth, Jennifer Faber, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
CNS Drugs|October 17, 2025
The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI CohortPatrick Silva, Marina A Costa, Laetitia Gaspar, et al.
Neurobiology of Disease|February 29, 2024
Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph diseaseMafalda Raposo, Jeannette Hübener-Schmid, Rebecca Tagett, et al.
The Lancet Regional Health. Europe|January 5, 2026
Patient-reported, psychosocial and health economic outcomes in mild to moderate Friedreich's ataxia: baseline results of the PROFA studyMarcus Grobe-Einsler, Stéphanie Borel, Maresa Buchholz, et al.
Annals of Neurology|December 13, 2022
Clinically Meaningful Magnetic Resonance Endpoints Sensitive to Preataxic Spinocerebellar Ataxia Types 1 and 3Jayashree Chandrasekaran, Emilien Petit, Young Woo Park, et al.
Journal of Neurology|November 3, 2022
The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factorsHolger Hengel, Peter Martus, Jennifer Faber, et al.
Journal of Neurology|November 18, 2023
Correction to: The frequency of non‑motor symptoms in SCA3 and their association with disease severity and lifestyle factorsHolger Hengel, Peter Martus, Jennifer Faber, et al.
Neuropathology and Applied Neurobiology|February 17, 2023
A standardised protocol for blood and cerebrospinal fluid collection and processing for biomarker research in ataxiaMagda M Santana, Laetitia S Gaspar, Maria M Pinto, et al.
Ebiomedicine|November 28, 2025
Quantitative susceptibility mapping at 7T as a biomarker of post- and interictal extravascular iron in patients with focal epilepsyNina Rebecca Held, Tobias Bauer, Rüdiger Stirnberg, et al.
Journal of Neurology|April 17, 2025
Optimizing selectivity of the Cerebellar Cognitive Affective Syndrome Scale by use of correction formulas, and validation of its German versionAndreas Thieme, Kerstin Rubarth, Raquel van der Veen, et al.
Journal of Neurology|December 21, 2024
Subtypes of cognitive impairment in cerebellar disease identified by cross-diagnostic cluster-analysis: results from a German multicenter studyQi Liu, Kerstin Rubarth, Jennifer Faber, et al.
Pageof 10